Melanoma

Genzyme Molecular Oncology Patents Newly Discovered Immunogens

Published in Cancer Weekly, November 13th, 2001

Genzyme Molecular Oncology (GZMO) has been issued a U.S. patent for the discovery of novel synthetic peptides and pharmaceutical compositions useful as therapeutic melanoma vaccines.

Discovered by Genzyme's antigen discovery group led by Charles A. Nicolette, PhD, the peptide ligands are superior immunogens when compared with the native gp100 epitope. The newly issued melanoma antigen patent provides synthetic peptide ligand variants of the 209 T-cell epitope of gp100 that may be useful in developing potent melanoma vaccines.

"Issuance of this patent is a key milestone for Genzyme Molecular Oncology," said Gail Maderis, president of Genzyme...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry